AI Article Synopsis
- - Lebrikizumab showed significant improvements in itching, sleep disruption from itching, and overall quality of life for patients with moderate-to-severe atopic dermatitis in two Phase 3 trials over 16 weeks compared to a placebo treatment.
- - The study analyzed data from two trials (ADvocate1 and ADvocate2), focusing on how improvements in itching and sleep interference related to quality of life scores using the Dermatology Life Quality Index (DLQI).
- - Results indicated that patients who responded positively to itch relief and sleep improvement reported better quality of life outcomes, demonstrating that addressing itch can significantly enhance patients' overall well-being.
Article Abstract
Background: Lebrikizumab improved itch, interference of itch on sleep, and quality of life (QoL) in patients with moderate-to-severe atopic dermatitis (AD), in two Phase 3 trials at 16 weeks compared to placebo.
Objectives: We assess improvements in itch and sleep interference due to itch and their impact on QoL measurements after treatment.
Methods: Data were analyzed from ADvocate1 (NCT04146363) and ADvocate2 (NCT04178967) in patients with moderate-to-severe AD. QoL was evaluated using Dermatology Life Quality Index (DLQI) at Week 16 in patients (>16 years of age) who were itch responders/non-responders (defined as ≥4-point improvement in Pruritus Numeric Rating Scale) or Sleep-Loss Scale responders/non-responders (defined as ≥2-point improvement in itch interference on sleep).
Results: In ADvocate1 and ADvocate2, significantly greater proportions of itch responders had a clinically meaningful improvement in measures related to QoL (DLQI scores (0/1), ≤5 DLQI total score and ≥4-point DLQI improvement) compared to itch non-responders. In both studies, a significantly greater proportion of Sleep-Loss Scale responders, reported a DLQI score of (0/1), DLQI total score of ≤5 and DLQI improvement of ≥4 points compared to Sleep-Loss Scale non-responders.
Conclusions: Improvement in itch and sleep interference due to itch is associated with improvement in the QoL of patients after treatment with lebrikizumab for moderate-to-severe AD.
Unlabelled: ClinicalTrials.gov registration NCT04146363 (ADvocate1) and NCT04178967 (ADvocate2).
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/09546634.2024.2329240 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Improvement in quality of life in patients treated with lebrikizumab monotherapy is mediated by improvement in itch and sleep: Results from two Phase 3 trials in patients with moderate-to-severe atopic dermatitis.
Clin Exp Dermatol
December 2024
Department of Dermatology, Emory University, Atlanta, USA.
Pruritus is a hallmark symptom of atopic dermatitis (AD) and is known to worsen patients' health-related quality of life. Lebrikizumab is a high-affinity monoclonal antibody which binds IL-13, a dominant cytokine implicated in AD. This study includes data from two Phase 3 randomized controlled trials assessing the efficacy and safety of lebrikizumab in patients with moderate-to-severe AD, ADvocate1 (NCT04146363) and ADvocate2 (NCT04178967).
View Article and Find Full Text PDFAssociation of sleep disturbance and itch intensity with quality of life impairment and disease severity in prurigo nodularis.
Br J Dermatol
December 2024
Department of Dermatology, University of Maryland School of Medicine, Baltimore, MD, USA.
Exploring the content validity of the EQ-5D-5L and four bolt-ons (skin irritation, self-confidence, sleep, social relationships) in atopic dermatitis and chronic urticaria.
Qual Life Res
December 2024
Acaster Lloyd Consulting Ltd, London, UK.
Background: The objective of this study was to assess the content validity of the EQ-5D-5L and four bolt-ons: skin irritation, self-confidence, social relationships and sleep, for people with atopic dermatitis (AD) and chronic urticaria (CU).
Methods: Adults with AD or CU in the United Kingdom, with varying levels of severity, participated in either online or in-person semi-structured interviews. During the interviews, participants were first asked about the symptoms and impacts of their condition.
Chronic kidney disease-associated pruritus: a comparison of instruments and associations with patient-reported outcomes using an electronic patient-reported outcome survey in Europe.
Clin Kidney J
October 2024
Arbor Research Collaborative for Health, Ann Arbor, USA.
Background: The associations between self-reported chronic kidney disease-associated pruritus (CKD-aP) and patient-reported outcomes (PROs) have been reported using various instruments to assess itch. Data collection via multiple CKD-aP instruments allows the evaluation of different domains and measurements of CKD-aP burden and may help tailor data capture for future research or clinical care.
Methods: An electronic PRO (ePRO) survey was distributed to European hemodialysis (HD) patients enrolled in the Dialysis Outcomes and Practice Patterns Study (DOPPS) in 2021-23.
Real-world evidence on the benefits of optimal itch relief and skin clearance in atopic dermatitis management: a study from the TARGET-DERM AD registry.
J Dermatolog Treat
December 2024
Departments of Dermatology and Pediatrics, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
In atopic dermatitis (AD), the real-world impact of achieving itch and skin lesion treatment targets compared to partial improvement remains unclear. We assessed the relationship between itch relief (reduction in Worst Itch Numeric Rating Scale [WI-NRS]) and skin clearance (Investigator Global Assessment [IGA] 0/1) with other patient-reported outcomes. Using TARGET-DERM AD registry data on adults receiving standard-of-care treatment, we described and modeled the relationship of itch severity (Worst Itch Numeric Rating Scale [WI-NRS]) and skin lesion severity (IGA) outcomes with patient-reported (quality of life ([DLQI)], AD severity [(POEM]), sleep ([Sleep-NRS]), and skin pain [(Pain-NRS]).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!